The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Circulating free DNA derived from active chromatin as a predictive biomarker for clinical benefit to checkpoint inhibitor-based therapies in metastatic leiomyosarcoma.
 
Carlos Diego Lopes
Travel, Accommodations, Expenses - Roche
 
Hsin-Ta Wu
Employment - Aqtual
Stock and Other Ownership Interests - Aqtual
 
Abdulazeez Salawu
Honoraria - Bayer; Medison
Consulting or Advisory Role - Astellas Pharma; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Knight Therapeutics; Medison; Taiho Pharmaceutical
Research Funding - Amgen; EMD Serono; PTC Therapeutics; SERVIER; Torl Biotherapeutics
 
Lee-Anne Stayner
No Relationships to Disclose
 
Katharine Dilger
Employment - Aqtual
Stock and Other Ownership Interests - Aqtual
 
Abha Gupta
No Relationships to Disclose
 
Aaron Hansen
Consulting or Advisory Role - Astellas Pharma; Bayer; Eisai; Janssen; Merck
Research Funding - Advancell (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Macrogenics (Inst); Merck (Inst); Roche/Genentech (Inst); Seagen (Inst); Tyra Biosciences (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer
 
Anna Spreafico
Consulting or Advisory Role - Alentis Therapeutics; Bristol-Myers Squibb; GlaxoSmithKline; Merck
Research Funding - Alentis Therapeutics (Inst); Alkermes (Inst); ALX Oncology (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Nubiyota (Inst); Pfizer (Inst); Replimune (Inst); Roche (Inst); Seagen (Inst); SERVIER (Inst); Symphogen (Inst); Teva (Inst); Treadwell Therapeutics (Inst)
 
Philippe Bedard
Honoraria - Boehringer Ingelheim
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bicara Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); LegoChem Biosciences (Inst); Lilly (Inst); Medicenna (Inst); Merck (Inst); Novartis (Inst); Sanofi (Inst); Seagen (Inst); Takeda (Inst); Zymeworks (Inst)
(OPTIONAL) Uncompensated Relationships - Janssen Oncology; Lilly; Repare Therapeutics; Roche/Genentech; Seagen; Zymeworks
 
Maggie Louie
Employment - Aqtual
Stock and Other Ownership Interests - Aqtual
 
Lillian Siu
Leadership - Treadwell Therapeutics (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Amgen; Arvinas; AstraZeneca; Daiichi Sankyo/UCB Japan; Gilead Sciences; GlaxoSmithKline; Incyte; LTZ Therapeutics; Marengo Therapeutics; Medicenna; Merck; Navire; Nerviano Medical Sciences; Pangea; Pangea; Relay Therapeutics; Roche; Seagen; Tubulis GmbH; Voronoi Health Analytics
Research Funding - 23andMe (Inst); Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); LegoChem Biosciences (Inst); Loxo/Lilly (Inst); Marengo Therapeutics (Inst); Medicenna (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Takara Bio (Inst)
 
Albiruni Abdul Razak
Consulting or Advisory Role - Alexion Pharmaceuticals; Boehringer Ingelheim; Clinical Research Malaysia; Inhibrx; Medison; UpToDate
Research Funding - 23 and Me; Abbisko Therapeutics (Inst); Abbvie; Adaptimmune; Amgen; AstraZeneca (Inst); Boehringer Ingelheim; Bristol-Myers Squibb; Cogent Biosciences (Inst); Daiichi Sankyo; Deciphera; Frontier Therapeutics; Gilead Sciences (Inst); GlaxoSmithKline; Intensity Therapeutics (Inst); Iterion Therapeutics; Karyopharm Therapeutics; Kelun (Inst); Merck; Neoleukin Therapeutics; Pfizer; Polaris (Inst); Rain Therapeutics; Roche/Genentech; Symphogen
Expert Testimony - Medison